SGMO · CIK 0001001233 · operating
Sangamo Therapeutics is a clinical-stage genomic medicine company developing gene therapies and cell therapies for serious genetic and acquired diseases. The company's pipeline includes ST-920, a gene therapy in Phase 1/2 development for Fabry disease; SB-525, a gene therapy in Phase 3 clinical trials for moderately severe to severe hemophilia A; and TX200, a chimeric antigen receptor engineered regulatory T cell therapy in Phase 1/2 studies for prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation. Preclinical programs focus on tauopathies, ALS/FTD, and Huntington's disease.
The company operates through strategic collaborations and partnerships with major pharmaceutical and biotechnology firms including Pfizer, Sanofi, Novartis, Biogen, Kite Pharma, Genentech, and others. These partnerships support both clinical development and preclinical research efforts across its therapeutic focus areas.
Sangamo maintains its headquarters in Richmond, California, with a workforce of approximately 183 full-time employees. The company was incorporated in Delaware in 1995 and trades on the Nasdaq under the ticker SGMO.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.49 | $-0.49 | +66.9% | |
| 2023 | $-1.48 | $-1.48 | -18.4% | |
| 2022 | $-1.25 | $-1.25 | -1.6% | |
| 2021 | $-1.23 | $-1.23 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | — | — | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-17 | 0001628280-25-013088 | SEC ↗ |
| 2023-12-31 | 2024-03-13 | 0001628280-24-010788 | SEC ↗ |
| 2022-12-31 | 2023-02-23 | 0001628280-23-004666 | SEC ↗ |
| 2021-12-31 | 2022-02-24 | 0001628280-22-003819 | SEC ↗ |
| 2020-12-31 | 2021-02-24 | 0001628280-21-003069 | SEC ↗ |
| 2019-12-31 | 2020-02-28 | 0001628280-20-002582 | SEC ↗ |
| 2018-12-31 | 2019-03-01 | 0001564590-19-005808 | SEC ↗ |
| 2017-12-31 | 2018-03-01 | 0001564590-18-004163 | SEC ↗ |
| 2016-12-31 | 2017-02-28 | 0001564590-17-002900 | SEC ↗ |
| 2015-12-31 | 2016-02-18 | 0001564590-16-012882 | SEC ↗ |
| 2014-12-31 | 2015-02-25 | 0001564590-15-000950 | SEC ↗ |
| 2013-12-31 | 2014-02-24 | 0001193125-14-065170 | SEC ↗ |
| 2012-12-31 | 2013-02-26 | 0001193125-13-076887 | SEC ↗ |